Holen Sie sich die Stockscreener-App
11.04
0.45%
0.0539
Schlusskurs vom Vortag:
$10.99
Offen:
$11.02
24-Stunden-Volumen:
235.86K
Relative Volume:
0.56
Marktkapitalisierung:
$217.88M
Einnahmen:
$244.06M
Nettoeinkommen (Verlust:
$87.01M
KGV:
6.0637
EPS:
1.8213
Netto-Cashflow:
$105.95M
1W Leistung:
-2.30%
1M Leistung:
-33.41%
6M Leistung:
-29.50%
1J Leistung:
-3.75%
1-Tages-Spanne:
$10.99
$11.35
1-Wochen-Bereich:
$10.49
$11.74
52-Wochen-Spanne:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Firmenname
Keros Therapeutics Inc
Sektor
Branche
Telefon
617-314-6297
Adresse
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Compare KROS vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
11.05 | 216.70M | 244.06M | 87.01M | 105.95M | 1.8213 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.71 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.66 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
705.49 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
312.82 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-10 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-01-21 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Herabstufung | Wedbush | Outperform → Neutral |
| 2024-12-16 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-12-16 | Bestätigt | Oppenheimer | Outperform |
| 2024-12-13 | Bestätigt | H.C. Wainwright | Buy |
| 2024-12-12 | Herabstufung | BTIG Research | Buy → Neutral |
| 2024-12-12 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-12-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Eingeleitet | Jefferies | Buy |
| 2024-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-23 | Eingeleitet | Guggenheim | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-02-21 | Eingeleitet | William Blair | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-07-31 | Eingeleitet | Wedbush | Outperform |
| 2023-07-26 | Eingeleitet | BofA Securities | Buy |
| 2023-02-14 | Eingeleitet | Cowen | Outperform |
| 2022-10-18 | Eingeleitet | Truist | Buy |
| 2022-07-26 | Eingeleitet | BTIG Research | Buy |
| 2020-12-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-04 | Eingeleitet | Jefferies | Buy |
| 2020-05-04 | Eingeleitet | Piper Sandler | Overweight |
| 2020-05-04 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget
What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - MarketBeat
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics adds former Lyell CFO to board By Investing.com - Investing.com India
Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks
Keros Therapeutics adds former Lyell CFO to board - Investing.com
Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan
Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan
Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan
Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan
Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewswire
KROS Technical Analysis & ETF Price Forecast - Intellectia AI
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Multiple Conferences - TipRanks
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Finanzdaten der Keros Therapeutics Inc-Aktie (KROS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):